All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-EPCAM chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Mouse EPCAM. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EPCAM antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of multiple myeloma.
CAR Construction : G8.8 scFv-41BB-CD28ζ Fig.1 Flow cytometry of EpCAM expression on the indicated target cell lines. 3T3 cells do not express EpCAM antigen, while both 4T1 (BALB/c breast cancer cell line) and MC38 (C57BL/6J colon cancer cell line) cells are EpCAM positive. Qin, D., Li, D., Zhang, B., Chen, Y., Liao, X., Li, X., Alexander, P. B., Wang, Y., & Li, Q. J. (2020). Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology, 9(1), 1806009. |
CAR Construction : G8.8 scFv-41BB-CD28ζ Fig.2 BALB/c derived EpCAM CAR-T cells specifically kill 4T1 cells in vitro. 4T1 and 3T3 cell lines were incubated with CAR-T or untransduced control T cells at the indicated E:T ratios for 12 h. CAR-T cytotoxicity was calculated by measuring LDH in the culture medium, which is released by lysed cells. Means of triplicate wells per group are shown. Data were analyzed from two independent experiments and presented as the mean ± SEM. Qin, D., Li, D., Zhang, B., Chen, Y., Liao, X., Li, X., Alexander, P. B., Wang, Y., & Li, Q. J. (2020). Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology, 9(1), 1806009. |
CAR Construction : G8.8 scFv-41BB-CD28ζ Fig.3 In vivo activity of mouse EpCAM CAR-T cells. 4T1 tumor volumes after treatment with EpCAM CAR-T or control T cells. BALB/c mice were inoculated with 1 × 105 4T1-luciferase cells on the right flank, after which 3 × 106 EpCAM CAR-T (orange) or control T cells (gray) were intravenously injected into tumor-bearing mice on day 7. Tumor volumes were monitored twice a week (n=5 mice per arm). Qin, D., Li, D., Zhang, B., Chen, Y., Liao, X., Li, X., Alexander, P. B., Wang, Y., & Li, Q. J. (2020). Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology, 9(1), 1806009. |
CAR Construction : G8.8 scFv-41BB-CD28ζ Fig.4 Alveolar cells express EpCAM and are targeted by EpCAM CAR-T cells. Representative IHC staining of EpCAM antigen expression of intestine (left) and lung (right) collected on day 3 after CAR-T cell transfer. Scale bar=200 µm (upper row), 100 µm (lower row). Qin, D., Li, D., Zhang, B., Chen, Y., Liao, X., Li, X., Alexander, P. B., Wang, Y., & Li, Q. J. (2020). Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology, 9(1), 1806009. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-EPCAM (G8.8) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-WFY3518). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION